Open access
Open access
Powered by Google Translator Translator

Psychiatry

Near Hanging: evaluation and management.

29 Nov, 2022 | 14:14h | UTC

Near Hanging: evaluation and management – Chest (PDF)

 


Podcast | Opioid use disorder and acute pain in hospitalized patients.

29 Nov, 2022 | 14:05h | UTC

#366 Opioid Use Disorder and Acute Pain in the Hospitalized Patient – The Curbsiders

 


SR | Antipsychotic dose reduction compared to dose continuation for people with schizophrenia.

29 Nov, 2022 | 13:59h | UTC

Antipsychotic dose reduction compared to dose continuation for people with schizophrenia – Cochrane Library

Summary: Reduction in the dose of antipsychotics for people with schizophrenia – Cochrane Library

 


SR | E-cigarettes are more effective than traditional nicotine-replacement methods in helping people quit smoking.

27 Nov, 2022 | 22:26h | UTC

Electronic cigarettes for smoking cessation – Cochrane Library

News Release: E-cigarettes are more effective than nicotine-replacement therapy in helping smokers quit – University of Oxford

Commentaries: 

Latest Cochrane Review finds high certainty evidence that nicotine e-cigarettes are more effective than traditional nicotine-replacement therapy (NRT) in helping people quit smoking – Cochrane Library

Expert reaction to Cochrane review on electronic cigarettes for smoking cessation – Science Media Centre

 

Commentary on Twitter

 


Consensus Paper | Prevention of alcohol withdrawal syndrome in the surgical ICU.

27 Nov, 2022 | 22:22h | UTC

Prevention of alcohol withdrawal syndrome in the surgical ICU: an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document – Trauma Surgery & Acute Care Open

 


ED-initiated buprenorphine: basics, barriers, and beyond the ED.

27 Nov, 2022 | 22:16h | UTC

ED-Initiated Buprenorphine: Basics, Barriers, and Beyond the ED – emDocs

 


SR | Pharmacological interventions for people with borderline personality disorder.

27 Nov, 2022 | 22:11h | UTC

Pharmacological interventions for people with borderline personality disorder – Cochrane Library

Summary: What are the benefits and risks of medication for people with borderline personality disorder? – Cochrane Library

 


Review | Public health measures and prevention of alcohol-associated liver disease.

27 Nov, 2022 | 22:14h | UTC

Public Health Measures and Prevention of Alcohol-Associated Liver Disease – Journal of Clinical and Experimental Hepatology

 

Commentary from one of the authors on Twitter

 


SR | Shared decision‐making interventions for people with mental health conditions.

27 Nov, 2022 | 22:10h | UTC

Shared decision‐making interventions for people with mental health conditions – Cochrane Library

Summary: Shared decision-making interventions for people with mental health conditions – Cochrane Library

 


RCT | One-session treatment compared with multisession CBT in children aged 7-16 years with specific phobias.

27 Nov, 2022 | 22:07h | UTC

One-session treatment compared with multisession CBT in children aged 7 16 years with specific phobias: the ASPECT non-inferiority RCT – Health Technology Assessment

 

Commentary on Twitter

 


M-A | Risk of cardiovascular diseases associated with medications used in ADHD.

25 Nov, 2022 | 12:16h | UTC

Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis – JAMA Network Open

Commentaries: 

Paying Attention to Attention-Deficit/Hyperactivity Disorder Medications and Cardiovascular Risk – JAMA Network Open

Meta-Analysis Finds ADHD Drugs Not Linked To Risk Of Cardiovascular Disease – Reporter Health

 


Review | Psychiatric issues among health professionals.

24 Nov, 2022 | 13:29h | UTC

Psychiatric Issues Among Health Professionals – Medical Clinics of North America

 


SR | Pharmaceutical interventions for emotionalism after stroke.

22 Nov, 2022 | 13:24h | UTC

Pharmaceutical interventions for emotionalism after stroke – Cochrane Library 

 


Post-trial follow-up | A brief intervention to prevent alcohol use can have sustained effects among high-risk adolescents.

22 Nov, 2022 | 13:08h | UTC

Effect of Selective Personality-Targeted Alcohol Use Prevention on 7-Year Alcohol-Related Outcomes Among High-risk Adolescents: A Secondary Analysis of a Cluster Randomized Clinical Trial – JAMA Network Open 

 

Commentary on Twitter 

 


Cohort Study | Association of antidepressant use during pregnancy with risk of neurodevelopmental disorders in children.

21 Nov, 2022 | 14:33h | UTC

Association of Antidepressant Use During Pregnancy With Risk of Neurodevelopmental Disorders in Children – JAMA Internal Medicine (link to abstract – $ for full-text) 

Commentaries: 

Antidepressant Use During Pregnancy Not Associated With Neurodevelopmental Risk in Children – Psychiatric News Alert 

Antidepressants in Pregnancy Do Not Affect Child Neurodevelopment – HealthDay 

 

Commentary on Twitter 

https://twitter.com/JAMAInternalMed/status/1593046260440776704 

 


M-A | Pharmacological interventions on smoking cessation.

18 Nov, 2022 | 13:12h | UTC

Pharmacological interventions on smoking cessation: A systematic review and network meta-analysis – Frontiers in Pharmacology

 


RCT | Extending the duration of prequit treatment with varenicline did not increase smoking abstinence rates.

17 Nov, 2022 | 12:22h | UTC

Effect of Extending the Duration of Prequit Treatment With Varenicline on Smoking Abstinence: A Randomized Clinical Trial – JAMA Network Open

 

Commentary on Twitter

https://twitter.com/JAMANetworkOpen/status/1591128623947591680

 


M-A | The response of subgroups of patients with schizophrenia to different antipsychotic drugs.

11 Nov, 2022 | 13:13h | UTC

The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis – The Lancet Psychiatry (link to abstract – $ for full-text)

 

Commentary on Twitter (thread – click for more)

 


RCT | Mindfulness-based stress reduction vs. escitalopram for the treatment of adults with anxiety disorders.

10 Nov, 2022 | 14:09h | UTC

Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial – JAMA Psychiatry (free for a limited period)

Commentaries:

Mindfulness worked as well for anxiety as drug in study – Associated Press

Meditation works as well as a popular drug to reduce anxiety, study finds – NPR

 

Commentary on Twitter

 


Cohort Study | Association of hormone therapy with depression during menopause.

9 Nov, 2022 | 12:17h | UTC

Association of Hormone Therapy With Depression During Menopause in a Cohort of Danish Women – JAMA Network Open

Commentaries:

Expert reaction to study looking at HRT and depression during the menopause – Science Media Centre

Oral, Transdermal Hormone Therapy for Menopause Before Age 50 May Increase Risk of Depression – Psychiatric News Alert

 

Commentary on Twitter

 


Cohort Study | Associations between childhood trauma and childhood psychiatric disorders in Brazil.

9 Nov, 2022 | 12:15h | UTC

Associations between childhood trauma and childhood psychiatric disorders in Brazil: a population-based, prospective birth cohort study – The Lancet Psychiatry

Commentary: Birth cohort study reveals the mental health burden of trauma in childhood – University of Bath

 


RCT | Efficacy and safety of methylphenidate and behavioral parent training for children aged 3–5 years with ADHD.

9 Nov, 2022 | 12:09h | UTC

Efficacy and safety of methylphenidate and behavioural parent training for children aged 3–5 years with attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled, and sham behavioural parent training-controlled trial – The Lancet Child & Adolescent Health (link to abstract – $ for full-text)

 

Commentary on Twitter (thread – click for more)

 


NICE Guideline | Self-harm: assessment, management and preventing recurrence.

7 Nov, 2022 | 12:58h | UTC

Self-harm: assessment, management and preventing recurrence – National Institute for Health and Care Excellence

 


Updated systematic review on cannabis and other plant-based treatments for chronic pain.

7 Nov, 2022 | 12:39h | UTC

Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain – Agency for Healthcare Research and Quality

Related:

Systematic Review: Cannabis-based products for chronic pain.

Podcast: #338 LIVE! Medical Cannabis: Is it still dope? – The Curbsiders

Medicinal Cannabis for Chronic Pain: The Bermuda Triangle of Low Quality Studies, Countless Meta-analyses and Conflicting Recommendations – European Journal of Pain

RCT: Effect of medical marijuana card ownership on pain, insomnia, and affective disorder symptoms in adults. 

Cohort Study: Long-term cannabis use is associated with cognitive deficits and smaller hippocampal volume in midlife. 

AHA Scientific Statement | How does cannabis use affect brain health? Caution advised, more research needed.

M-A: Birth outcomes of neonates exposed to marijuana in utero. 

Cannabis-related allergies: an international overview and consensus recommendations.

Review: Cannabis-based medicines and medical cannabis for chronic neuropathic pain.

Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions.

The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use.

Cannabis products are being sold as sleep remedies – here’s the evidence about their effectiveness.

Guideline: Medical cannabis or cannabinoids for chronic pain.

Cannabis and Cannabinoid Analgesia position statement – “Due to the lack of high-quality clinical evidence, the IASP does not currently endorse general use of cannabis and cannabinoids for pain relief.”

NICE Guideline: Cannabis-Based Medicinal Products

Consensus recommendations for perioperative management of cannabis and cannabinoid-based medicine users

Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain – Agency for Healthcare Research and Quality

Short Review: Drug Interactions with Cannabinoids

Meta-Analysis: Cannabinoids Not Effective for Cancer-Related Pain

Review: Considerations for cannabinoids in perioperative care by anesthesiologists.

Review: Cannabis-based Medicines and the Perioperative Physician

Study: Cannabis Use Disorder May Increase the Risk of Cardiovascular Events in Major Elective Surgeries

Perspective: If You Smoke Pot, Your Anesthesiologist Needs To Know

Perioperative Care of Cannabis Users: A Comprehensive Review of Pharmacological and Anesthetic Considerations

 


RCT | Naltrexone-bupropion and behavior therapy, alone and combined, for binge-eating disorder.

7 Nov, 2022 | 12:27h | UTC

Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial – The American Journal of Psychiatry

News Release: People With Binge-eating Disorder Benefit From Specific Behavioral Therapy and Medication – Yale School of Medicine

Commentary: Behavioral Therapy Plus Naltrexone-Bupropion Combination May Reduce Binge Eating – Psychiatric News Alert

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.